Preferentially Expressed Antigen in Melanoma (PRAME) Peptide
PRAME
Reactivity: Mammalian
Host: Synthetic
BP, WB, IHC
Catalog No. ABIN936776
Quick Overview for Preferentially Expressed Antigen in Melanoma (PRAME) Peptide (ABIN936776)
Target
PRAME
(Preferentially Expressed Antigen in Melanoma (PRAME))
Origin
Mammalian
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Peptide Type
- Synthetic
-
Sequence
- AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
-
Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of PRAME antibody,
Alternative Names: PRAME control peptide, PRAME antibody Blocking Peptide, Anti-PRAME Blocking Peptide, Preferentially Expressed Antigen In Melanoma Blocking Peptide, MAPE Blocking Peptide, OIP4 Blocking Peptide
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C long term.
-
-
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
-
Background
- PRAME functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. PRAME prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
-
Molecular Weight
- 56 kDa
Target
-
You are here:
